ArticleClinical endoscopy2026
A pilot study of a novel tapered and flared fully covered self-expandable metal stent for unresectable malignant distal biliary obstruction: a multicenter study in Japan.
Article in Clinical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond cylindrical stents: does a tapered-and-flared design improve biliary drainage?Clinical endoscopy · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the feasibility and clinical outcomes of a novel tapered and flared, fully covered, self-expandable metal stent (TF-FCSEMS) for unresectable malignant distal biliary obstruction (UMDBO).
methodsThis multicenter retrospective study included 40 patients who underwent transpapillary placement of a TF-FCSEMS (10-mm cylindrical body with an 8-mm tapered distal end) for UMDBO between May 2023 and July 2024. The primary outcome was time to recurrent biliary obstruction (TRBO). Secondary outcomes included technical and clinical successes, adverse events (AEs), and overall survival.
resultsTechnical and clinical success rates were 100% and 98%, respectively. During a median follow-up period of 271 days, recurrent biliary obstruction (RBO) occurred in 10 (26%) of the 39 patients who achieved clinical success. The median TRBO was 539 days (95% confidence interval, 389-not reached), and the non-RBO rates at 3, 6, and 12 months were 94%, 71%, and 61%, respectively. Symptomatic stent migration occurred in 2 patients (5.1%), while asymptomatic migration was observed in 3 (7.7%). Post-endoscopic retrograde cholangiopancreatography pancreatitis occurred in four patients (10%). Non-occlusion cholangitis developed in five (13%) patients, mostly with tumor-related duodenal stenosis. All AEs were managed conservatively or endoscopically.
conclusionsTF-FCSEMS appears to be a feasible and acceptable treatment option for UMDBO. Further prospective studies are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.